Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 2,683 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: OPIOID Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users

NCT01030406
View directory record Official record
Conditions
Opioid Abuse
Interventions
40/0mg taken first, 80/0mg taken first, 40/240mg taken first, 80/480mg taken first, 0/0mg taken first
Drug
Lead sponsor
Acura Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 27, 2026, 6:49 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Community Driven Substance Use Recovery for High Opioid Overdose Areas

NCT05260047
View directory record Official record
Conditions
Substance Use, Mental Health Issue, Opioid Use, Medication Assisted Treatment
Interventions
IMANI, Telehealth MAT, Traditional MAT plus Referral and Linkage
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
8
States / cities
Bridgeport, Connecticut • Hartford, Connecticut • New Britain, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 27, 2026, 6:49 AM EDT
Completed No phase listed Observational

A Naturalistic Experiment Evaluating the Impact of Medicaid Treatment Reimbursement Changes on Opioid Prescribing and Patient Outcomes Among Patients With Back Pain

NCT03393143
View directory record Official record
Conditions
Back Pain, Neck Pain
Interventions
Not listed
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 65 Years
Enrollment
2,748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 27, 2026, 6:49 AM EDT
Completed Phase 4 Interventional Results available

Extended Release Naltrexone for Opioid-Dependent Youth

NCT01843023
View directory record Official record
Conditions
Drug Dependence
Interventions
Extended Release Naltrexone, Psychosocial Treatment, Buprenorphine
Drug · Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
15 Years to 21 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 27, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users

NCT01759446
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Placebo taken first, Generic H/A taken first, Vycavert taken first, Generic H/A plus i taken first, Generic H/A plus p taken first
Drug
Lead sponsor
Acura Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 27, 2026, 6:49 AM EDT
Completed Phase 2 Interventional

Buprenorphine Maintenance for Opioid Addicts - 2

NCT00000203
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 27, 2026, 6:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation

NCT02639273
View directory record Official record
Conditions
AUD
Interventions
Nalmefene, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1

NCT00023283
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Substance Abuse, Intravenous
Interventions
Buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 27, 2026, 6:49 AM EDT
Terminated Phase 2 Interventional

Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder

NCT04262193
View directory record Official record
Conditions
Opioid-use Disorder, Sleep
Interventions
Suvorexant, Suvorexant Placebo
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 27, 2026, 6:49 AM EDT
Recruiting Phase 2Phase 3 Interventional

Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children

NCT04724252
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 6:49 AM EDT
Completed Not applicable Interventional Results available

Telehealth-Clinical Advocacy Project

NCT04911426
View directory record Official record
Conditions
Substance Use
Interventions
Telehealth
Behavioral
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 27, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence

NCT02437344
View directory record Official record
Conditions
Opioid Dependence
Interventions
CI-581aa, Naltrexone titration and XR-NTX initiation
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 27, 2026, 6:49 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers

NCT07064564
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone implant, 14.4 grams, Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg
Drug
Lead sponsor
Akyso Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 27, 2026, 6:49 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery

NCT00877799
View directory record Official record
Conditions
Acute Pain
Interventions
CR845, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 27, 2026, 6:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Chronic Pain, Opioid Use, and Epidermal Nerve Fiber Density

NCT04801498
View directory record Official record
Conditions
Chronic Pain, Opioid Use, Nerve Disorders
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 27, 2026, 6:49 AM EDT
Terminated Not applicable Interventional

Cessation of Long-term Opioid Therapy in Chronic Pain Patients

NCT02132221
View directory record Official record
Conditions
Chronic Pain
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 27, 2026, 6:49 AM EDT
Active, not recruiting Not applicable Interventional

Developing an Opioid Taper Intervention Before Total Joint Arthroplasty

NCT05788016
View directory record Official record
Conditions
Arthritis Knee, Arthritis Hip, Chronic Pain
Interventions
opioid taper
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 27, 2026, 6:49 AM EDT
Completed Phase 1 Interventional Results available

Marijuana in Combination With Opioids in Palliative and Hospice Patients

NCT03233633
View directory record Official record
Conditions
Pain
Interventions
Medical Marijuana
Drug
Lead sponsor
The Connecticut Hospice Inc.
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Branford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 27, 2026, 6:49 AM EDT
Not listed Not applicable Interventional

Cryoablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients

NCT05276258
View directory record Official record
Conditions
Pain, Pain, Postoperative
Interventions
cryoSPHERE Ablation, Bupivacaine
Device · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 27, 2026, 6:49 AM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

NCT00315848
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal delivery system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
10
States / cities
Huntsville, Alabama • Phoenix, Arizona • Westminster, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated May 3, 2006 · Synced Oct 27, 2026, 6:49 AM EDT
Completed Phase 1 Interventional

Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor

NCT00706576
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Infusion of opioid growth factor
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 27, 2026, 6:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Decision Support to Improve System Naloxone Co-prescribing

NCT06271668
View directory record Official record
Conditions
Medication Abuse, Harm Reduction, Opioid Overdose, Opioid Prescribing
Interventions
Naloxone Co-prescribing Clinical Decision Support (CDS)
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 89 Years
Enrollment
114,272 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 6:49 AM EDT
Completed Phase 4 Interventional Results available

A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration

NCT01453374
View directory record Official record
Conditions
Opioid Dependence
Interventions
VIVITROL 380mg
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 27, 2026, 6:49 AM EDT
Terminated Phase 2 Interventional Results available

CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome

NCT04104646
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
CHF6563, Morphine, CHF6563 matched placebo, Morphine matched placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
Up to 7 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Las Vegas, Nevada • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 27, 2026, 6:49 AM EDT